GASTROENTEROLOGY

CTC Promising As Adjunct to Colonoscopy

BY DAMIAN MCNAMARA

ORLANDO — CT colonography continues to show promise as an adjunct to colonoscopy for colorectal cancer screening, according to study findings. Dr. Ruben D. Acosta and his associates assessed 170 average-risk patients at the National Naval Medical Center in Bethesda, Md. All patients had computed tomographic colonography (CTC) followed by a colonoscopy. Polyp histology was used to compare results from 92 participants with a positive CTC and another 60 randomly selected patients with a negative CTC. Mean age was 56 years, 32% were women, and 82% were white.

In previous studies, the researchers had demonstrated that CTC could detect polyps 6 mm or larger as accurately as colonoscopy on a per-patient basis. In the current study, the histology showed that 6 of the 60 patients with a negative CTC had adenoma and 2 had advanced adenoma. In addition, 58% of patients with a normal CTC had at least one polyp detected on colonoscopy. Dr. Acosta said at the annual meeting of the American College of Gastroenterology.

“This underscores the complementary relationship between CTC and colonoscopy programs,” said Dr. Acosta, a gastroenterologist at the center.

Of the 348 polyps detected by colonoscopy, including 87 hyperplastic polyps and 84 adenomas. In addition, CTC missed seven advanced adenomas (an overall 3% miss rate). Two of the seven advanced adenomas missed by CTC were smaller than 10 mm. The miss rate for CTC was inversely associated with poly size. Dr. Acosta said. As expected, 79% of the 222 polyps missed by CTC, but detected by follow-up colonoscopy, were smaller than 6 mm. Among the 16% of missed polyps in the 7-mm to 9-mm range, 15 polyps were hyperplastic and 17 were adenomas. The remaining polyps that were missed by CTC were 10 mm or larger and included five hyperplastic polyps and five adenomas.

The CTC miss rate for polyps greater than 10 mm was 4.5%. Dr. Acosta said this miss rate is comparable to the rate of large polyps missed with tandem colonoscopy (Am. J. Gastroenterol. 2006;101:343-50). In this systematic review of six studies with 465 patients, researchers found a 2.1% miss rate for polyps 10 mm or larger. Dr. Acosta reported having no disclosures related to his presentation.

FOB Tests Useful in Colon Ca Screening

BY MICHAEL VLESSIDES

BANFF, ALTA. — A colorectal screening program in Ontario has proven successful in detecting high-risk adenomas and colorectal cancer in patients referred because of positive fecal occult blood test results or a family history of colorectal cancer.

“About 2 years ago, the Ontario Ministry of Health announced this new colorectal screening program, which is based on fecal occult blood [FOB] testing for average-risk patients and colonoscopy for those with a first-degree relative with colorectal cancer,” said Dr. William G. Paterson at the Canadian Digestive Diseases Week. “And certainly amongst the GI community there was controversy as to whether a screening program based on FOB testing was the best approach,” he added.

To answer this question, Dr. Paterson and his colleagues reviewed the charts of 764 patients referred to the program; 122 were referred because of positive FOB tests. Of those, 14 patients were found to have cancer (11.4% diagnostic yield) and 30 had high-risk adenomas (24.6% diagnostic yield). The remaining 642 patients screened through the program had a family history of colorectal cancer. Eleven cases of cancer (1.7% diagnostic yield) and 37 high-risk adenomas (5.8% diagnostic yield) were found. The yield for this co-

IMPORTANT TREATMENT CONSIDERATIONS

PRISTIQ 50-mg Extended-Release Tablets are indicated for the treatment of major depressive disorder in adults.

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of PRISTIQ or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.

Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior.

Families and caregivers of patients being treated with antidepressants should be advised of the need to monitor patients.

• Development of a potentially life-threatening serotonin syndrome may occur with SNRIs and SSRIs, including PRISTIQ, particularly with concomitant use of serotonergic drugs, including triptans, and with drugs that impair the metabolism of serotonin (including MAOIs). If concomitant use is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Concomitant use of PRISTIQ with serotonin precursors is not recommended.

• Patients receiving PRISTIQ should have regular monitoring of blood pressure since sustained increases in blood pressure were observed in clinical studies. Pre-existing hypertension should be controlled and patients with pre-existing hypertension or other underlying conditions that might be compromised by increases in blood pressure should be considered.

• PRISTIQ must not be used concomitantly with an MAOI or within 14 days of stopping an MAOI. Allow 7 days after stopping PRISTIQ before starting an MAOI.

Contraindications

• PRISTIQ is contraindicated in patients with a known hypersensitivity to PRISTIQ or venlafaxine.

Prisquet is not approved for use in pediatric patients.
GASTROENTEROLOGY

For the treatment of adults with major depressive disorder

The start is just the beginning

It’s not just about starting your adult patients with MDD on therapy; it’s about helping them toward their treatment goals. Patients should be periodically reassessed to determine the need for continued treatment.1

PRISTIQ® 50 mg:
• SNRI therapy with efficacy proven in 8-week clinical studies
• One recommended therapeutic dose from the start
• Discontinuation rate due to adverse events comparable to placebo in 8-week clinical studies

PRISTIQ® desvenlafaxine 50 mg

think beyond start™

• SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, NSAIDs, warfarin, and other anticoagulants may add to this risk.
• Mydriasis has been reported in association with PRISTIQ; therefore, patients with raised intracranial pressure or those at risk of acute narrow-angle glaucoma (angle-closure glaucoma) should be monitored.
• PRISTIQ is not approved for use in bipolar depression. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine the risk of bipolar disorder.
• As with all antidepressants, PRISTIQ should be used cautiously in patients with a history or family history of mania or hypomania, or with a history of seizure disorder.
• Caution is advised in administering PRISTIQ to patients with cardiovascular, cerebrovascular, or lipid metabolism disorders. Increases in blood pressure and small increases in heart rate were observed in clinical studies with PRISTIQ. PRISTIQ has not been evaluated systematically in patients with a recent history of myocardial infarction, unstable heart disease, uncontrolled hypertension, or cerebrovascular disease.
• Dose-related elevations in fasting serum total cholesterol, LDL (low density lipoprotein) cholesterol, and triglycerides were observed in clinical studies. Measurement of serum lipids should be considered during PRISTIQ treatment.
• On discontinuation, adverse events, some of which may be serious, have been reported with PRISTIQ and other SSRIs and SNRIs. Abrupt discontinuation of PRISTIQ has been associated with the appearance of new symptoms. Patients should be monitored for symptoms when discontinuing treatment. A gradual reduction in dose (by giving 50 mg of PRISTIQ less frequently) rather than abrupt cessation is recommended whenever possible.
• Dosage adjustment (50 mg every other day) is necessary in patients with severe renal impairment or end-stage renal disease (ESRD). The dose should not be escalated in patients with moderate or severe renal impairment or ESRD.
• Products containing desvenlafaxine and products containing venlafaxine should not be used concomitantly with PRISTIQ.
• Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. Discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia.
• Intestinal lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported.

Adverse Reactions
• The most commonly observed adverse reactions in patients taking PRISTIQ vs placebo for MDD in short-term fixed-dose premarketing studies (incidence ≥5% and twice the rate of placebo in the 50-mg dose group) were nausea (22% vs 10%), dizziness (15% vs 5%), hypomania (10% vs 4%), constipation (9% vs 4%), and decreased appetite (5% vs 2%).


Please see brief summary of Prescribing Information on adjacent page.